ABSTRACT Airway perforation is a potentially lethal complication from tracheal or mediastinal malignancies that require complex management. Advanced thyroid cancer is known to have high morbidity, and patients with tracheal metastatic lesions are vulnerable to injury. Therapeutic management typically comprises a combination of surgical and nonoperative treatment modalities, whose adverse effects can lead to significant airway injury. We present the case of a 67‐year‐old man with papillary thyroid carcinoma who developed a tracheocutaneous fistula following proton beam therapy and chemotherapy for metastatic disease. Airway repair and recanalization were successfully achieved through a combined surgical and bronchoscopic approach.
EBUS
‐Guided Incidental Finding of Pulmonary Vein Thrombosis: A Case Report and Literature Review
ABSTRACT Pulmonary vein thrombosis (PVT) is an uncommon but potentially fatal condition that is often underdiagnosed due to nonspecific clinical presentation. We report a case of a 47‐year‐old woman with a thrombus in the right inferior pulmonary vein incidentally found during a robotic‐assisted bronchoscopy biopsy (RAB) and endobronchial ultrasound (EBUS) performed for mediastinal evaluation and lymph node sampling. PVT was confirmed with computed tomography pulmonary angiography, and the patient was successfully treated with anticoagulation therapy. A review of the literature revealed that reports of PVT detected via EBUS are exceedingly rare and usually malignant in nature. To our knowledge, this is the first peer‐reviewed case report describing PVT identified incidentally during EBUS, underscoring the potential of this technique to reveal clinically significant vascular abnormalities.
D24-21 Paclitaxel-coated Balloon Dilation as an Effective Treatment for Bronchial Stenosis in Vacterl Association: A Case Report
Abstract Introduction VACTERL is an uncommon association of congenital anomalies that stands for vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities. In addition to these classical features, patients may present with airway abnormalities such as bronchial stenosis or bronchomalacia, which can lead to significant respiratory compromise. Severe bronchial stenosis is usually treated with open airway reconstruction or lung transplantation; however, this is associated with substantial risks, especially in patients with complicated congenital conditions. Interventional bronchoscopic techniques, such as paclitaxel-coated balloon dilatation, allow a less invasive alternative for restoring airway patency and reducing restenosis. We describe the case of a patient with VACTERL association and severe bronchial stenosis successfully treated with serial paclitaxel-coated balloon dilatations, avoiding the need for lung transplantation. Case description A 27-year-old male with VACTERL association presented with symptomatic left mainstem bronchial stenosis and complete right lung collapse. Bronchoscopic intervention was performed over lung transplantation because of the patient’s young age and high surgical risk. It revealed complete fibrotic obstruction of the right main bronchus and proximal stenosis of the left mainstem bronchus, measuring approximately 5-6 mm in diameter. Performing paclitaxel-coated balloon dilation showed progressive airway enlargement and clinical improvement. Under bronchoscopic guidance using a drug-coated balloon (diameter 8-10 mm, length 40 mm), which was placed in the narrowed segment and inflated for 2 minutes to expand the airway and deliver paclitaxel locally, thereby inhibiting cell proliferation and scar tissue formation. Subsequent follow-ups showed that the left mainstem bronchus diameter increased to 8-9 mm, with improvement in the airway patency and respiratory function, without any significant complications. Discussion Although the use of paclitaxel-coated balloon dilation for bronchial stenosis is still limited, this case illustrates its potential benefits as an adjunctive interventional therapy in patients with VACTERL association. The serial dilatations resulted in a progressive, sustained increase in airway diameter, from an initial 5-6 mm to approximately 8-9 mm at final follow-up in our patient (Figure 1). Compared with lung transplant, this intervention offers lower complication rates and the avoidance of chronic graft rejection and immunological complications, which are particularly relevant for young patients. This case report shows the potential of paclitaxel-coated balloon dilation as a safe, effective, and minimally invasive therapeutic option for managing bronchial stenosis in patients with complicated congenital disorders. This abstract is funded by: None
C79-06 Robotic Assisted Bronchoscopy With Endobronchial Pulsed Electric Field Ablation Behind an Obstructed Airway
Abstract Introduction Pulsed Electric Field (PEF) Ablation has been used as an adjunct therapy for cancer. Robotic-Assisted Bronchoscopy (RAB) enables precise access to pulmonary lesions for biopsy and ablative therapy. However, anatomic obstructions within the airway may prohibit access to peripheral targets. We report a case in which robotic bronchoscopy navigation for the delivery of PEF was not initially possible due to a new anatomic airway obstruction secondary to radiation fibrosis. We were able to utilize therapeutic bronchoscopy to re-cannulate the airway and deliver the PEF via the robotic bronchoscope. Case Report A 68-year-old man with a history of left lung adenocarcinoma was treated with surgery, chemoradiation and durvalumab consolidation therapy. Surveillance imaging 4 years later revealed consolidation in the right upper mediastinum. A bronchoscopy brush biopsy confirmed adenocarcinoma and received systemic chemotherapy. Later a PET-CT showed a non FDG avid enlarged right paratracheal lesion. Follow-up CT revealed complete obstruction of the right middle lobar bronchus with associated middle lobe collapse likely secondary to radiation. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) of the right paratracheal lesion confirmed malignancy on onsite cytopathology. Subsequently, we performed two PEF ablations targeting the involved lesion. Repeat PET-CT demonstrated two hypermetabolic foci in the right hilum and right supraclavicular region. However, the previously PEF treated paratracheal lesion was not PET avid. We used a RAB to navigate into the right upper lobe and identified the anterior segment to be obstructed in addition to the previously noted right middle lobe. Due to this, the robotic bronchoscope couldn’t be advanced to the right hilar PET avid lesion. Utilizing guidewires, balloon dilatation and fluoroscopy we re-cannulated the obstructed right upper lobe segment and subsequently advance the robotic bronchoscope to the target in the right upper lobe. Under cone-beam guidance, multiple biopsies were obtained and confirmed as malignant. Following this, the INUMI PEF needle was deployed. We delivered two PEF activations to the right hilar PET-avid lesion. Subsequent systemic staging using linear EBUS identified station 4R lymph node involvement, positive for malignancy on rapid onsite cytopathologic evaluation. The 4R lymph node was superior to the previously treated paratracheal lesion. We then deployed the INUMI PEF needle, and PEF ablation was performed successfully. Discussion To our knowledge, this is the first reported instance of combining robotic and therapeutic bronchoscopy to overcome airway obstruction to facilitate the distal treatment of peripheral target with PEF. This abstract is funded by: None
C44-26 Robotic-assisted Bronchoscopy for Fungal Lung Infections: Overcoming the Diagnostic Limitations of Bronchoalveolar Lavage (BAL) Antigen Testing
Abstract Introduction The diagnosis of fungal lung infections remains challenging as standard tests, such as bronchoalveolar lavage (BAL) antigen testing, often yield variable or inconclusive results. These limitations can delay appropriate therapy and may require additional tissue sampling for definitive diagnosis. Robotic-assisted bronchoscopy (RAB) biopsy has been primarily used as a minimally invasive technique for assessing suspicious peripheral pulmonary lesions (PPL). This case series highlights the diagnostic utility of RAB for identifying fungal infections within PPL when conventional BAL antigen analysis is non-diagnostic. Case Description Four patients with suspected infectious or malignant PPL underwent RAB-guided biopsy for diagnostic clarification, all yielding histopathologic confirmation of fungal disease. The first, a 73-year-old bilateral lung-transplant recipient with hemoptysis, had a negative BAL Aspergillus antigen despite RAB biopsy confirming Aspergillus infection. Similarly, a second 73-year-old man with chronic obstructive pulmonary disease (COPD) and esophageal adenocarcinoma had a negative BAL antigen, while RAB biopsy of bilateral cavitary lesions confirmed Aspergillus. Additionally, a 39-year-old woman with a nodule being evaluated for malignancy, had negative BAL Histoplasma antigen and PCR, whereas RAB biopsy confirmed Histoplasma capsulatum. In contrast, a 56-year-old woman with a right-lower-lobe nodule had a positive BAL Aspergillus antigen that aligned with the histopathologic biopsy findings. Discussion BAL-based antigen testing demonstrates variable diagnostic accuracy in fungal lung disease. Reported sensitivities for Aspergillus detection are typically high in meta-analysis, approximately 80%-90%, but clinical performance in the immunocompromised or high-risk patients is often substantially lower. Similarly, while BAL antigen testing for Histoplasma performs well in disseminated infections, it often fails to detect localized pulmonary disease. In this series, three out of four patients had negative BAL results in the presence of histopathologic confirmation of fungal infection. While current guidelines consider BAL positivity supportive of a “probable” diagnosis, tissue histopathology remains the gold standard for a “proven” infection. These findings emphasize the value and capability of RAB in obtaining direct tissue confirmation when conventional testing, such as BAL antigen analysis, is non-diagnostic. Conclusion RAB-guided biopsy of PPLs offers the opportunity for histopathologic confirmation of fungal infection when BAL testing is non-diagnostic. This approach can enhance upfront diagnostic yield in patients with suspected fungal pulmonary infections, avoiding delays in diagnosis and treatment initiation. This abstract is funded by: None
Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis
Background: Preparation for radioiodine (RAI) therapy in differentiated thyroid cancer (DTC) often requires thyroid hormone withdrawal (THW) to achieve thyrotropin (TSH) stimulation. Current guidelines recommend TSH ≥30 mIU/L, a target that prolongs hypothyroidism and worsens quality of life, yet rests on limited evidence. Objective: To evaluate the association between pre-RAI TSH levels and oncologic outcomes in adults with DTC prepared by THW. Methods: We conducted a systematic review and meta-analysis of studies comparing outcomes across pre-RAI TSH thresholds (<30 vs. ≥30, <60 vs. ≥60, and <90 vs. ≥90 mIU/L) in adults with DTC prepared by THW. Primary outcomes included disease-specific mortality, recurrence, and response to therapy. Searches in MEDLINE, Embase, Cochrane, and Scopus (inception to March 2025) identified eligible studies. Risk of bias was assessed using the CLARITY tool and certainty of evidence using GRADE. Pooled relative risks (RRs) were calculated using random-effects models. This systematic review was registered in PROSPERO (CRD42020158354). Results: This meta-analysis included eight retrospective cohort studies comprising a total of 4651 DTC patients, predominantly women (68.5%) with a mean age of 46 years. All patients underwent THW before RAI. Across all TSH thresholds examined (<30, <60, and <90 mIU/L), higher pre-RAI TSH levels were not associated with better treatment response, lower recurrence, or reduced mortality. Specifically, patients with higher pre-RAI TSH levels (≥30 mIU/L) did not have better oncologic outcomes compared with those with lower levels (<30 mIU/L). At 2- and 3-year follow-up, no significant differences were observed in excellent (pooled RR = 0.87; confidence interval [CI] 0.68–1.11) or indeterminate (RR = 1.28; CI 0.72–2.27) response rates. Similarly, recurrence rates did not differ (RR = 1.45; CI 0.83–2.55), and no study demonstrated a difference in disease-specific mortality across follow-up periods extending up to 10 years. The certainty of evidence for all outcomes was rated very low due to risk of bias, heterogeneity, and imprecision. Conclusions: The current evidence base is insufficient to support or refute the routine use of a specific TSH threshold before RAI administration. These findings question the recommendation to achieve TSH ≥30 mIU/L before RAI and highlight the need for trials to define the minimal effective level of TSH stimulation.
International Registry of thyroid cancer in Latin American (CaTaLiNA): epidemiology, clinical and follow-up study protocol in Latin American countries during the period 2023–2028
Introduction Differentiated thyroid cancer (DTC) is the most common endocrine malignancy, with a high 5-year survival rate of approximately 98%. Despite advances in diagnosis and treatment, up to 20% of patients experience recurrence, adversely affecting their quality of life. Predictive models have been developed to assess recurrence risk and guide clinical decision-making, but these models often face limitations such as retrospective design, lack of diversity in study populations and absence of external validation. The primary aim is to externally validate existing predictive models for DTC recurrence using prospective data from a diverse Latin American cohort. The secondary aim is to explore opportunities for model recalibration to improve their performance in our population. Methods and analysis The CaTaLiNA study is a multicentre prospective observational study conducted across 10 hospitals in five Latin American countries, including Ecuador, Peru, Uruguay and Mexico. Patients aged 18 years or older receiving treatment for DTC, such as the first thyroid surgery, active surveillance or radiofrequency ablation will be included. Recruitment will occur from November 2023 to June 2025, with follow-up extending until June 2028. Data collection will include baseline clinical, surgical and histological characteristics, treatment details and follow-up outcomes. Statistical analysis will follow the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis guidelines, using imputation strategies for missing data and evaluating calibration and discrimination of the prediction models. Calibration measures include the ratio of expected and observed events, calibration slope and calibration plot, while discrimination will be assessed using the C-index and area under the receiver operating characteristic curve. Ethics and dissemination This study protocol was approved by Comité de Ética de Investigación en Seres Humanos de la Universidad San Francisco de Quito USFQ ‘CEISH-USFQ’ APO-010–2023-CEIHS-USFQ Oficio No. 161-2023-CA-23030M-CEISH-USFQ. Results will be disseminated via peer-reviewed publications.
Spindle Epithelial Tumor with Thymus-Like Differentiation: The First Case Report from Ecuador
Effectiveness of Different Thyroid Stimulating Hormone Thresholds for Thyroid Hormone Withdrawal - Aided Radioiodine Ablation in Patients With Differentiated Thyroid Cancer: A Systematic Review and Meta - Analysis
Abstract Background: Patients with differentiated thyroid cancer (DTC) may benefit of radioiodine ablation (RAI) to reduce the probability of thyroid cancer recurrence. Guidelines recommend that thyroid stimulating hormone (TSH) of >30mIU/L before RAI to optimize treatment response. However, evidence regarding this recommendation is conflicting. We conducted a systematic review and meta-analysis to compare outcomes (thyroid cancer recurrence and survival at 10 years of follow up) of stimulated TSH threshold before RAI with primary analysis focus on <30 mIU/L versus ≥30 mIU/L, and subgroup analysis on <90 mIU/L versus ≥90 mIU/L in patients with DTC after initial total thyroidectomy. Methods: The protocol for this study is registered and available online (CRD42020158354). Briefly, we searched several databases from their inception to April 2020. Reviewers, working independently and in duplicate selected studies for inclusion, extracted data, and evaluated each study’s risk of bias. We excluded studies that used recombinant human thyroid stimulating hormone before ablation. Results: We included five retrospective cohort studies, which enrolled a total of 2,514 patients. Risk of bias was low in four studies and high in one study. Mean age was 47 years old (ranged from 40.7 to 47.9) and most of them were female (69%). The most common DTC type was papillary thyroid cancer (78%). From those articles that reported tumor characteristics, 48% had a size ≤2cm (T1b) and 47% >2cm. Moreover, 73% of the patients had no regional lymph metastasis (N0). Two studies reported radioiodine mean dose given of 30 and 100 mci. A total of 301 patients were included in the TSH threshold <30 mIU/L group and 1788 patients in the TSH ≥30 mIU/L group. Comparing stimulated TSH threshold before RAI (<30 mIU/L versus ≥30 mIU/L), there was difference in recurrence at 1 year (RR 2.46 (C.I. 1.09-5.55) and at 20 years (RR 1.71 (C.I. 1.19 – 2.47). However, there was no difference in mortality at 20 years (RR 0.53 (Confidence Interval (C.I.) 0.12-2.23). In addition, 10-years recurrence was not different when we compared <90 mIU/L versus ≥90 mIU/L TSH (RR 1.06; 95%CI: 0.88 – 1.27). Conclusions: Mortality do not differ between recommended TSH goal (≥30 mIU/L) vs <30 mIU/L in thyroid hormone withdrawal-aided radioiodine ablation in DTC patients. However, the risk of recurrence is reduced when patients achieved a TSH level >30 UI/mL. These results suggest that patients may need to reach a stimulated TSH ≥30 mIU/L stimulated TSH threshold to be treated. Randomized trials are needed to confirm these findings.
Thyroid Cancer Overdiagnosis and Overtreatment: a cross- sectional study at a thyroid cancer referral center in Ecuador
Abstract Background: In contrast to the rapid increase in thyroid cancer incidence, the mortality has remained low and stable over the last decades. In Ecuador, however, thyroid cancer mortality has increased. The objective of this study is to determine possible drivers of high rates of thyroid cancer mortality, through a cross-sectional analysis of all patients attending a thyroid cancer referral center in Ecuador.Methods: From June 2014 to December 2017, a cross-sectional study was conducted at the Hospital de Especialidades Eugenio Espejo, a regional reference public hospital for endocrine neoplasia in adults in Quito, Ecuador. We identified the mechanism of detection, histopathology and treatment modalities from a patient interview and review of clinical records. Results: Among 452 patients, 74.8% were young adults and 94.2% (426) were female. 13.7% had a family history of thyroid cancer, and patients’ median tumor size was 2 cm. The incidental finding was 54.2% whereas 45.8% was non-incidental. Thyroid cancer histology reported that 93.3% had papillary thyroid cancer (PTC), 2.7% follicular, 1.5% Hurtle cells, 1.6% medullary, 0.7% poor differentiated, and 0.2% anaplastic carcinoma. The mean MACIS (metastasis, age, completeness, invasion, and size) score was 4.95 (CI 4.15-5.95) with 76.2% of the thyroid cancer patients having MACIS score less than or equal to 6. The very low and low risk of recurrence was 18.1% (79) and 62% (271) respectively. An analysis of 319 patients with non-metastatic thyroid cancer showed that 10.7% (34) of patients had surgical complications. Moreover, around 62.5% (80 from 128 patients with thyroglobulin laboratory results) of TC patients had a stimulated-thyroglobulin value equal or higher than 2 ng/ml. Overall, a poor surgical outcome was present in 35.1% (112) patients. Out of 436 patients with differentiated thyroid carcinoma, 86% (375) received radioactive iodine. Conclusion: Thyroid cancer histological characteristics and method of diagnosis are like those described in other reports without any evidence of the high frequency of aggressive thyroid cancer histology. However, we observed evidence of overtreatment and poor surgical outcomes that demand additional studies to understand their association with thyroid cancer mortality in Ecuador.